AstraZeneca: positive results in lung cancer trial
(CercleFinance.com) - AstraZeneca said on Thursday that its cancer immunotherapy, Imfinzi, improved the pathologic complete response (pCR) in a late-stage study in patients with resectable lung cancer.
Results from a planned interim analysis of a Phase III trial showed treatment with Imfinzi—in combination with neoadjuvant chemotherapy before surgery—demonstrated a statistically significant and meaningful improvement in pathologic complete response (pCR) compared to neoadjuvant chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC).
A statistically significant improvement in major pathologic response (MPR) was also observed, the drugmaker said.
AstraZeneca has several ongoing registrational trials focused on testing Imfinzi in earlier stages of lung cancer, as treating the disease early provides the best chance for a cure.
Yet, lung cancer will still recur within five years for the majority of patients despite chemotherapy and successful surgery.
Data shows that only around 56-65% of patients with Stage II disease will survive for five years. This decreases to 24-41% for patients with Stage III disease.
Copyright (c) 2022 CercleFinance.com. All rights reserved.